Phathom Pharmaceuticals Inc 's ability to collect accounts receivable sequentially worsen to 3.02, indicating more challenging environment then in the second quarter 2026, but still, it is a far cry from any concerns. Phathom Pharmaceuticals Inc 's Accounts Receivable average collection period in the Sep 30 2026 quarter, has increased to 121 days, from 119 days, in the Jun 30 2026 quarter.

If we take a look into Healthcare sector 154 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 1371, from overall ranking in the second quarter 2026 at 3104.

What is Receivable Turnover Ratio?
What is Phathom Pharmaceuticals Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PHAT Receivables Turnover Ratio	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Receivable Change	92.87 %	90.07 %	121.99 %	101.38 %	165.01 %
Y / Y Revenue Change	71.14 %	88.02 %	104.43 %	94.12 %	202.74 %
Receivable Turnover Ratio (TTM)	3.02	3.07	3.08	3.16	3.23
PHAT's Total Ranking	# 1371	# 3104	# 2508	# 1891	#
Accounts Receivable average collection period days	121	119	118	115	113
Seq. Receivable Change	10.45 %	20.69 %	3.32 %	40.04 %	8.85 %
Seq. Revenue Change	14.07 %	27.4 %	1.25 %	16.32 %	25.32 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 40
Healthcare Sector	# 155
Overall Market	# 1371

Receivable Turnover Ratio Statistics
High	Average	Low
0.85	0.45	0.07
(Jun 30 2026)		(Sep 30 2024)

PHAT Company Profile • Back to PHAT Efficiency Comparisons • Compare PHAT Receivables Turnover Ratio to its Competitors

Financial Statements
Phathom Pharmaceuticals Inc 's Accounts Receivable	$ 108 Millions	Visit PHAT's Balance sheet
Phathom Pharmaceuticals Inc 's Sales TTM	$ 275 Millions	Visit PHAT's Income Statement
Sources of PHAT's Revenues		Visit PHAT's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
PHAT's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
PHAT's Growth Rates	PHAT's Roa	PHAT's Inventory Turnover Ratio	PHAT's Dividend Comparisons
PHAT's Profitability Ratios	PHAT's Roi	PHAT's Asset Turnover Ratio	PHAT's Dividend Growth
PHAT's Valuation Ratios	PHAT's Roe	PHAT's Financial Strength Ratios	PHAT's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Sep 30 2026	Receivable at quarter ending Sep 30 2026
Stryker Corp	6.99	$ 26,300.000 Millions	$ 3,761.500 Millions
Boston Scientific Corporation	6.96	$ 21,070.000 Millions	$ 3,028.750 Millions
Verastem Inc	6.95	$ 100.296 Millions	$ 14.430 Millions
Syndax Pharmaceuticals Inc	6.89	$ 289.431 Millions	$ 42.011 Millions
Hca Healthcare Inc	6.85	$ 78,701.000 Millions	$ 11,495.250 Millions
Ceribell Inc	6.77	$ 109.203 Millions	$ 16.138 Millions
Medpace Holdings Inc	6.73	$ 2,838.385 Millions	$ 421.525 Millions
Beone Medicines Ltd	6.69	$ 6,606.279 Millions	$ 987.953 Millions
Carlisle Companies Incorporated	6.67	$ 5,213.500 Millions	$ 781.625 Millions
Iradimed Corporation	6.62	$ 89.340 Millions	$ 13.487 Millions
3m Company	6.59	$ 25,247.000 Millions	$ 3,832.500 Millions
Baxter International Inc	6.55	$ 11,784.000 Millions	$ 1,799.500 Millions
Haemonetics Corporation	6.48	$ 1,382.737 Millions	$ 213.396 Millions
Zevra Therapeutics Inc	6.40	$ 140.548 Millions	$ 21.947 Millions
Bruker Corporation	6.39	$ 3,512.500 Millions	$ 549.350 Millions
Labcorp Holdings Inc	6.38	$ 14,594.500 Millions	$ 2,286.925 Millions
Bionano Genomics Inc	6.36	$ 31.085 Millions	$ 4.888 Millions
Healthcare Services Group Inc	6.36	$ 1,879.860 Millions	$ 295.784 Millions
Intellia Therapeutics Inc	6.33	$ 52.887 Millions	$ 8.355 Millions
Gilead Sciences Inc	6.29	$ 30,988.000 Millions	$ 4,929.000 Millions
Integra Lifesciences Holdings Corp	6.26	$ 1,656.786 Millions	$ 264.861 Millions
Atara Biotherapeutics Inc	6.23	$ 4.019 Millions	$ 0.645 Millions
Orthofix Medical Inc	6.18	$ 835.683 Millions	$ 135.265 Millions
Neogen Corporation	6.17	$ 884.120 Millions	$ 143.371 Millions
Vertex Pharmaceuticals Inc	6.10	$ 12,951.600 Millions	$ 2,123.550 Millions
Mimedx Group Inc	6.06	$ 303.363 Millions	$ 50.077 Millions
Harvard Bioscience Inc	6.02	$ 90.339 Millions	$ 15.007 Millions
Rxsight Inc	6.00	$ 122.088 Millions	$ 20.336 Millions
Zai Lab Limited	5.99	$ 441.727 Millions	$ 73.769 Millions
Avantor Inc	5.98	$ 6,635.600 Millions	$ 1,110.300 Millions

Date modified: 2026-10-30T13:20:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.